|
Afatinib (INN; trade name Gilotrif in the US and Giotrif in Europe, previously Tomtovok and Tovok〔) is a drug approved in United States, Europe, Taiwan, Mexico, Chile and Japan as well as other countries for the first-line treatment of patients with distinct types of metastatic (EGFR mutation positive) non-small cell lung carcinoma (NSCLC), developed by Boehringer Ingelheim.〔〔〔 It acts as an irreversible covalent inhibitor of the receptor tyrosine kinases epidermal growth factor receptor (EGFR) and erbB-2 (]). ==Medical uses== It has received regulatory approval for use as a treatment for non-small cell lung cancer,〔〔〔〔 although there is emerging evidence to support its use in other cancers such as breast cancer.〔 In October 2010 a Phase III trial in NSCLC patients called ''Lux-Lung 5'' began with this drug.〔 Fall 2010 interim results suggested the drug extended progression-free survival threefold compared to placebo, but did not extend overall survival.〔 In May 2012, the Phase IIb/III trial ''Lux-Lung 1'' came to the same conclusion.〔 In January 2015 a Phase III trial in people with NSCLC suggested the drug extended life expactancy in stage IV NSCLC Adenocarcinoma with EGFR Mutation type del 19-positive tumors, compared to cisplatin-based chemotherapy by a year (33 months vs. 21 months). Phase II results for breast cancer that over-expresses the protein human epidermal growth factor receptor 2 (Her2-positive breast cancer) were described as promising by the authors, with 19 of 41 patients achieving benefit from afatinib.〔 Double-blind Phase III trials are under way to confirm or refute this finding. Her2-negative breast cancers showed limited or no response to the drug.〔 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Afatinib」の詳細全文を読む スポンサード リンク
|